Adding PD1 Inhibitor to Neoadjuvant Chemotherapy Significantly Increases the pCR Rate in High-Risk, Early-Stage ER-positive, HER2-negative Breast Cancer By Ogkologos - February 12, 2025 763 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 7FL and KEYNOTE-756 studies Source RELATED ARTICLESMORE FROM AUTHOR Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer Patient Guide on Bone Health in Cancer Now Available Also in French Lung Cancer Death Rates Among Women in Europe Are Finally Levelling Off MOST POPULAR FDA Grants Accelerated Approval to Sotorasib for KRAS G12C-mutated NSCLC June 4, 2021 Quizartinib Approval Adds New Treatment Option for AML, Including in Older... August 15, 2023 Adding 24 Months of ADT Improves Metastasis-Free Survival in Patients with... May 27, 2024 Qué saber sobre los diferentes tipos de mastectomías para el cáncer... November 15, 2023 Load more HOT NEWS Bowel Cancer Data Reinforce Need to Reduce Unnecessary Antibiotic Use [ESMO... FDA Grants Accelerated Approval to Tisotumab Vedotin-tftv for Recurrent or Metastatic... Scottish Soccer Star Who Just Announced Breast Cancer Diagnosis Scores Goal,... FDA Approves Selinexor for Refractory or Relapsed Multiple Myeloma
